MMWR Morb Mortal Wkly Rep. 2023 Apr 21;72(16):445-449. doi: 10.15585/mmwr.mm7216a6.
At-home rapid antigen COVID-19 tests were first authorized by the Food and Drug Administration in late 2020 (1-3). In January 2022, the White House launched COVIDTests.gov, which made all U.S. households eligible to receive free-to-the-user at-home test kits distributed by the U.S. Postal Service (2). By May 2022, more than 70 million test kit packages had been shipped to households across the United States (2); however, how these kits were used, and which groups were using them, has not been reported. Data from a national probability survey of U.S. households (COVIDVu), collected during April-May 2022, were used to evaluate awareness about and use of these test kits (4). Most respondent households (93.8%) were aware of the program, and more than one half (59.9%) had ordered kits. Among persons who received testing for COVID-19 during the preceding 6 months, 38.3% used a COVIDTests.gov kit. Among kit users, 95.5% rated the experience as acceptable, and 23.6% reported being unlikely to have tested without the COVIDTests.gov program. Use of COVIDTests.gov kits was similar among racial and ethnic groups (42.1% non-Hispanic Black or African American [Black]; 41.5% Hispanic or Latino [Hispanic]; 34.8% non-Hispanic White [White]; and 53.7% non-Hispanic other races [other races]). Use of other home COVID-19 tests differed by race and ethnicity (11.8% Black, 44.4% Hispanic, 45.8% White, 43.8% other races). Compared with White persons, Black persons were 72% less likely to use other home test kits (adjusted relative risk [aRR] = 0.28; 95% CI = 0.16-0.50). Provision of tests through this well-publicized program likely improved use of COVID-19 home testing and health equity in the United States, particularly among Black persons. National programs to address availability and accessibility of critical health services in a pandemic response have substantial health value.
家庭用抗原 COVID-19 快速检测试剂盒于 2020 年末首次获得美国食品药品监督管理局(FDA)批准(1-3)。2022 年 1 月,白宫推出 COVIDTests.gov,使所有美国家庭都有资格通过美国邮政服务免费接收家庭用检测试剂盒(2)。截至 2022 年 5 月,已经向全美 7000 多万户家庭发送了试剂盒包裹(2);然而,这些试剂盒的使用情况以及哪些群体在使用这些试剂盒尚未有报道。2022 年 4 月至 5 月期间,利用来自全美概率抽样家庭的 COVIDVu 数据评估了人们对该项目的了解情况和这些检测试剂盒的使用情况(4)。大多数被调查家庭(93.8%)了解该项目,超过一半(59.9%)订购过试剂盒。在过去 6 个月内接受过 COVID-19 检测的人群中,有 38.3%使用了 COVIDTests.gov 试剂盒。在试剂盒使用者中,95.5%的人对体验表示可接受,23.6%的人表示如果没有 COVIDTests.gov 项目,他们不太可能进行检测。COVIDTests.gov 试剂盒的使用在不同种族和族裔群体中相似(42.1%非西班牙裔黑人或非裔美国人[黑人];41.5%西班牙裔或拉丁裔[西班牙裔];34.8%非西班牙裔白人[白人];53.7%非西班牙裔其他种族[其他种族])(4)。不同种族和族裔群体对其他家庭 COVID-19 检测的使用情况存在差异(黑人 11.8%,西班牙裔 44.4%,白人 45.8%,其他种族 43.8%)(1)。与白人相比,黑人使用其他家庭检测试剂盒的可能性低 72%(调整后的相对风险[aRR] = 0.28;95%CI = 0.16-0.50)。通过该广为人知的项目提供检测,可能会提高美国 COVID-19 家庭检测的使用率和卫生公平性,尤其是在黑人中。在大流行应对期间,为解决关键卫生服务的可及性和可获得性而制定的国家方案具有重要的健康价值。